CC 92328
Alternative Names: CC-92328Latest Information Update: 25 Oct 2021
At a glance
- Originator Dragonfly Therapeutics
- Developer Celgene Corporation
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma